Streetbeat News

Revenues

IPG

Interpublic Gr of Cos (NYSE:IPG) has been evaluated by 6 analysts, with a mix of neutral and buy ratings. The average 12-month price target is now $35.0, down from $37.45, indicating a 6.54% decrease. Analysts from UBS, Citigroup, Barclays, Morgan Stanley, and Wells Fargo have adjusted their price targets, with most lowering their estimates. IPG's financial performance shows revenue growth but below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 2:00 pm

SGBX

Safe & Green Holdings (SGBX) has announced a purchase order expected to generate $11.3 million in revenue over the next six months, starting immediately.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 2:00 pm

HAYW

Six analysts have provided ratings on Hayward Holdings (NYSE:HAYW) with an average 12-month price target of $13.75, down from $14.70. The ratings include 1 bullish, 1 somewhat bullish, and 4 indifferent. Analysts from Jefferies, Stifel, Goldman Sachs, and Keybanc have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Hayward Holdings, a manufacturer of swimming pool equipment, has seen a -10.18% decline in revenue growth and has below industry average net margin and ROE. The company's market capitalization is below industry benchmarks, and it has a conservative debt-to-equity ratio of 0.86.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 2:00 pm

SGBX

Safe & Green Holdings' subsidiary has received a purchase order to supply over 150 modular units to an existing infrastructure solutions customer. This order represents a continuation and expansion of the company's relationship with the customer, potentially indicating strong performance and reliability of their modular units.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 2:00 pm

LEXX

Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced the availability of a broadcast discussing the potential of GLP-1 drugs in treating various diseases and the company's proprietary DehydraTECH platform, which enhances the delivery of active molecules into the bloodstream. DehydraTECH has shown improved delivery into brain tissue and superior bioabsorption for oral administration, which could significantly impact the efficacy of GLP-1 agonists in treating conditions such as Alzheimer's, Parkinson's, heart disease, cancer, autoimmune diseases, and more.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 1:43 pm

META

The Chan Zuckerberg Initiative (CZI) is shifting its focus to become a 'science-first philanthropy,' as reported by Business Insider. This strategic pivot will see CZI investing the majority of its resources into scientific research, integrating its Biohub Network with CZI for efficiency. The organization's first COO, Josué Estrada, is set to leave in March, with Marc Malandro, VP of operations for science, taking over. This move follows layoffs in CZI's education segment and the discontinuation of its education policy grants portfolio, reflecting a similar 'year of efficiency' campaign by Meta Platforms Inc. (NASDAQ:META).

Portfolio Pulse from Rounak Jain

January 11, 2024 | 1:39 pm

GP

GreenPower Motor Company Inc. has delivered 10 EV Star Cab and Chassis to a global retailer's Canadian unit for last and middle-mile home deliveries in the Toronto area. The vehicles, financed by a Canadian leasing company, are zero-emission electric vehicles with a 7,000-pound capacity and 150-mile range. GreenPower also delivered various other electric vehicles during the quarter, including school buses and transit buses, and has over 100 EV Star Cab and Chassis ready for delayed delivery. Lion Truck Body, a GreenPower subsidiary, delivered 40 truck bodies in the same quarter.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 1:37 pm

MTEK

Maris-Tech, which may be referred to as MTEK, has announced preliminary revenue figures for the fiscal year 2023, estimating revenues to be around $4 million.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 1:36 pm

ABBV

EOLS

RVNC

AbbVie Inc (NYSE:ABBV) maintains a strong position in the aesthetics market with a 68% share of Botox sales, despite competition and calls for stronger FDA warnings on botulinum toxin products. At the J.P. Morgan healthcare conference, CCO Jeffrey Stewart expressed confidence in Botox's market resilience. AbbVie's acquisition of Allergan in 2020 bolstered its market dominance, especially as its drug Humira lost exclusivity. The company also sees potential in its newer drugs, Skyrizi and Rinvoq. Revance Therapeutics Inc (NASDAQ:RVNC) and Evolus Inc (NASDAQ:EOLS) are emerging competitors with products like Daxxify and Jeuveau.

Portfolio Pulse from Vandana Singh

January 11, 2024 | 1:31 pm

ELIQ

Electriq Power, potentially referenced as ELIQ, has projected sales of $1.3 million for Q4. The company also reaffirmed its revenue forecast for 2024, expecting to generate between $20 million and $30 million.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 1:27 pm